Stereoselective and nonstereoselective pharmacokinetics of rabeprazole – an overview
Stereoselective and nonstereoselective pharmacokinetics of rabeprazole – an overview
复制标题
DOI：
10.1080/00498254.2017.1307470
复制
发表时间：
2018-04
期刊：
影响因子：
1.8
通讯作者：
Ranjeet P. Dash;R. Rais;N. Srinivas
中科院分区：
文献类型：
--
作者：
Ranjeet P. Dash;R. Rais;N. Srinivas
摘要1.质子泵抑制剂已被广泛用于治疗胃酸分泌增加引起的疾病，如消化性溃疡、胃食管反流病等。质子泵抑制剂类中有几种获批药物，最新条目代表先前获批外消旋药物的单一对映体药物。3.尽管具有高度的结构相似性，雷贝拉唑，被证明具有一些独特的区别于其他药物的类。雷贝拉唑的一个关键区别特征与其药代动力学处置中多态代谢的参与较少有关。4.该综述旨在提供雷贝拉唑的药代动力学数据，包括药物相互作用研究，其中雷贝拉唑是犯罪药物或受害药物。5.由于雷贝拉唑独特的代谢处置，包括手性相关的可能问题，治疗考虑的其他观点也被提供。
Abstract 1. Proton pump inhibitors have been extensively used for the treatment of ailments due to increased gastric acid secretion such as peptic ulcers, gastroesophageal reflux disease, etc. 2. There are several approved drugs in the proton pump inhibitor class with the latest entries representing single enantiomer drugs of the previously approved racemic drugs. 3. Despite having a high degree of structural resemblance, rabeprazole, was shown to possess some unique differentiation from other drugs in the class. One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmacokinetic disposition. 4. The review was aimed to provide pharmacokinetic data of rabeprazole from several clinical studies including drug–drug interaction studies where rabeprazole was either a perpetrator drug or victim drug. 5. Additional perspectives on therapy considerations due to the unique metabolic disposition of rabeprazole including the possible issues related to chirality were provided.